Catalyst
Slingshot members are tracking this event:
ContraVir Doses First Patients in Head-to-Head Study of CMX157 vs. Viread for Treating Hepatitis B
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CTRV |
|
|
||||
Additional Information
The Phase 2a will enroll a total of 60 treatment-naïve patients with chronic HBV infection. This study consists of a sequential dose escalation, with 10 patients per cohort receiving four weeks of a once-daily dose of either 5, 10, 25, 50 or 100 mg of CMX157, and two patients per cohort receiving 300 mg of TDF, the standard dose of Viread.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 21, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cmx157, Viread, Hepatitis B, Hbv Infection
